Home Cytoskeletal Signaling MLCK

MLCK

Cytoskeletal Signaling

EGFR IGF-1R c-Met c-Kit ALK Tie-2 HER2 PDGFR c-RET Trk receptor TAM receptors (Tyro-3,Axl,and Mertk) CSF-1R Ephrin receptor ACK DDR ROS1 Pyk2 Tyro3 Axl Mertk Fer kinase RON Insulin Receptor
  • All (8)
  • MLCK Inhibitors (6)
  • MLCK Antagonist (1)
  • MLCK Modulator (1)
  • New MLCK Products
Cat.No. Product Name Information Product Use Citations Product Validations
S8388 ML-7 HCl ML-7 is an inhibitor of smooth muscle myosin light chain kinase (MLCK) with a Ki value of 0.3 µM and displays reversible, ATP-competitive inhibition of Ca2+-calmodulin-dependent and -independent smooth muscle MLCKs. ML-7 also inhibits PKA and PKC with Ki of 21 μM and 42 μM, respectively.
Proc Natl Acad Sci U S A, 2025, 122(8):e2421717122
Cell Mol Life Sci, 2025, 82(1):201
Commun Biol, 2025, 8(1):607
Verified customer review of ML-7 HCl
S3699 2,3-Butanedione-2-monoxime 2,3-Butanedione monoxime (BDM, Diacetyl monoxime, Diacetylmonoxime) is the well-characterized, low-affinity, non-competitive inhibitor of skeletal muscle myosin-II and inhibits skeletal and cardiac muscle contraction.
E5817New Sevasemten Sevasemten is a selective, orally active allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten reduces biomarkers of muscle damage and fibrosis, while enhancing muscle strength and functional activity in models of Duchenne muscular dystrophy.
S1573 Fasudil HCl Fasudil HCl, a potent and selective inhibitor of Rho kinase, displays less potent inhibiton over PKA, PKG, PKC and MLCK with Ki of 1.6, 1.6, 3.3, and 36 μM in cell-free assays, respectively. Fasudil is also a calcium channel blocker.
Stem Cell Res Ther, 2025, 16(1):597
Transl Oncol, 2025, 51:102209
J Immunother Cancer, 2024, 12(11)e009805
Verified customer review of Fasudil HCl
S8861 Mavacamten (MYK-461) Mavacamten (MYK-461, SAR439152) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy (HCM), one of the most prevalent heritable cardiovascular disorders.
Eur Heart J, 2025, ehaf813
Circ Res, 2025, S1525-0016(25)00760-9.
Circulation, 2023, 147(25):1919-1932
S6847 ML-9 HCl ML-9 HCl (ML-9 hydrochloride) is a selective and potent inhibitor of Akt kinase, myosin light chain kinase (MLCK) and stromal interaction molecule 1 (STIM1). This compound is also a potent inhibitor of Ca2+-permeable channels. It is a lysosomotropic agent targeting autophagy and cell death.
Cell Mol Life Sci, 2025, 82(1):201
PLoS Pathog, 2023, 19(3):e1011295
J Mol Endocrinol, 2019, 63(3):199-213
E2506 A-3 hydrochloride A-3 hydrochloride, a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases, againsts cAMP-dependent protein kinase (PKA) (Ki=4.3 µM), casein kinase II (CK2) (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM), also inhibits Protein Kinase C (PKC) and casein kinase I (CK1) with Ki values of 47 µM and 80 µM, respectively.
S2964 HA-100 dihydrochloride HA-100 dihydrochloride is an inhibitor of cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase with IC50 of 4 μM, 8 μM, 12 μM and 240 μM, respectively.
Adv Sci (Weinh), 2024, 11(4):e2304987
S8388 ML-7 HCl ML-7 is an inhibitor of smooth muscle myosin light chain kinase (MLCK) with a Ki value of 0.3 µM and displays reversible, ATP-competitive inhibition of Ca2+-calmodulin-dependent and -independent smooth muscle MLCKs. ML-7 also inhibits PKA and PKC with Ki of 21 μM and 42 μM, respectively.
Proc Natl Acad Sci U S A, 2025, 122(8):e2421717122
Cell Mol Life Sci, 2025, 82(1):201
Commun Biol, 2025, 8(1):607
 Verified customer review of ML-7 HCl
S3699 2,3-Butanedione-2-monoxime 2,3-Butanedione monoxime (BDM, Diacetyl monoxime, Diacetylmonoxime) is the well-characterized, low-affinity, non-competitive inhibitor of skeletal muscle myosin-II and inhibits skeletal and cardiac muscle contraction.
E5817New Sevasemten Sevasemten is a selective, orally active allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten reduces biomarkers of muscle damage and fibrosis, while enhancing muscle strength and functional activity in models of Duchenne muscular dystrophy.
S1573 Fasudil HCl Fasudil HCl, a potent and selective inhibitor of Rho kinase, displays less potent inhibiton over PKA, PKG, PKC and MLCK with Ki of 1.6, 1.6, 3.3, and 36 μM in cell-free assays, respectively. Fasudil is also a calcium channel blocker.
Stem Cell Res Ther, 2025, 16(1):597
Transl Oncol, 2025, 51:102209
J Immunother Cancer, 2024, 12(11)e009805
 Verified customer review of Fasudil HCl
S6847 ML-9 HCl ML-9 HCl (ML-9 hydrochloride) is a selective and potent inhibitor of Akt kinase, myosin light chain kinase (MLCK) and stromal interaction molecule 1 (STIM1). This compound is also a potent inhibitor of Ca2+-permeable channels. It is a lysosomotropic agent targeting autophagy and cell death.
Cell Mol Life Sci, 2025, 82(1):201
PLoS Pathog, 2023, 19(3):e1011295
J Mol Endocrinol, 2019, 63(3):199-213
S2964 HA-100 dihydrochloride HA-100 dihydrochloride is an inhibitor of cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase with IC50 of 4 μM, 8 μM, 12 μM and 240 μM, respectively.
Adv Sci (Weinh), 2024, 11(4):e2304987
E2506 A-3 hydrochloride A-3 hydrochloride, a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases, againsts cAMP-dependent protein kinase (PKA) (Ki=4.3 µM), casein kinase II (CK2) (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM), also inhibits Protein Kinase C (PKC) and casein kinase I (CK1) with Ki values of 47 µM and 80 µM, respectively.
S8861 Mavacamten (MYK-461) Mavacamten (MYK-461, SAR439152) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy (HCM), one of the most prevalent heritable cardiovascular disorders.
Eur Heart J, 2025, ehaf813
Circ Res, 2025, S1525-0016(25)00760-9.
Circulation, 2023, 147(25):1919-1932
E5817New Sevasemten Sevasemten is a selective, orally active allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten reduces biomarkers of muscle damage and fibrosis, while enhancing muscle strength and functional activity in models of Duchenne muscular dystrophy.